Tesamorelin Research Overview: FDA-Approved GHRH Analogue for Visceral Fat
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
Tesamorelin (brand name Egrifta) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that consists of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid group added to the N-terminus to increase stability. It received FDA approval in 2010 for the treatment of excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy.
Mechanism of Action
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. The resulting GH elevation drives IGF-1 production in the liver and promotes lipolysis (fat breakdown) in visceral adipose tissue.
Visceral fat selectivity: A key finding in tesamorelin research is its preferential effect on visceral (abdominal) fat compared to subcutaneous fat. This selectivity is thought to be mediated by the higher density of GH receptors in visceral adipocytes and their greater sensitivity to GH-stimulated lipolysis.
Preservation of pulsatile GH: Unlike exogenous recombinant GH, tesamorelin preserves the natural pulsatile pattern of GH secretion, which is important for maintaining physiological GH signaling.
FDA-Approved Indication: HIV Lipodystrophy
HIV-associated lipodystrophy is characterized by excess visceral fat accumulation (lipohypertrophy) and/or peripheral fat loss (lipoatrophy), caused by antiretroviral therapy. This condition increases cardiovascular risk and causes significant psychological distress.
Phase 3 LIPO trials: Two pivotal Phase 3 trials demonstrated that tesamorelin significantly reduced visceral adipose tissue (VAT) compared to placebo:
| Trial | VAT Reduction (Tesamorelin) | VAT Reduction (Placebo) | |-------|---------------------------|------------------------| | LIPO-010A | -15.2% | +5.0% | | LIPO-010B | -18.0% | +3.0% |
Research Beyond HIV Lipodystrophy
Non-alcoholic fatty liver disease (NAFLD): A randomized controlled trial published in Lancet HIV (2019) investigated tesamorelin in HIV-positive adults with NAFLD. Results showed significant reductions in liver fat content (measured by MRI) compared to placebo.
Cognitive function in aging: Research at Massachusetts General Hospital has investigated tesamorelin in older adults with mild cognitive impairment. Preliminary data suggest that tesamorelin-induced IGF-1 elevation may improve cognitive function.
Abdominal obesity in non-HIV populations: Research has explored tesamorelin for visceral fat reduction in non-HIV obese individuals, with positive results in Phase 2 studies.
Comparison with Other GHRH Analogues
| Parameter | Tesamorelin | Sermorelin | CJC-1295 (non-DAC) | |-----------|------------|-----------|---------------------| | Half-life | ~26 minutes | 10-20 minutes | ~30 minutes | | FDA approval | Yes (HIV lipodystrophy) | Withdrawn 2008 | No | | Visceral fat data | Extensive (Phase 3) | Limited | Limited | | IGF-1 elevation | Significant | Moderate | Moderate |
Summary
Tesamorelin is the only GHRH analogue with FDA approval, providing the most extensive clinical evidence base in its class. Its selective reduction of visceral fat, preservation of pulsatile GH secretion, and expanding research applications in NAFLD and cognitive aging make it a valuable research tool beyond its approved indication.
See Also: Sermorelin Research Overview | Ipamorelin + CJC-1295 Combination Research
Was this article helpful?
Click a star to rate